Agilent Technologies, Inc. research snapshot
A AI stock analysis currently reads Agilent Technologies as a high-quality life sciences, diagnostics, and applied markets supplier with recurring consumables and services, but with cyclical instrument demand, China exposure, tariff costs, and valuation sensitivity still important. At the July 8, 2026 data cutoff, A traded near $131.14 with a verified market capitalization near $37.11 billion. This page uses scenario ranges and source checks, not a certain stock price prediction, and is for informational use only.
Current price
$131.14
Market cap
$37.11 billion
AI score
69 / 100
Rating
Quality lab tools franchise, cyclical demand watch
Trend status
Recovered above key moving averages after Q2 2026 beat
Data cutoff (updated weekly)
July 8, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | Agilent sells instruments, software, consumables, services, diagnostics tools, and CDMO capabilities into lab workflows where accuracy, uptime, compliance, and method validation matter. | High |
| Moat | Moat comes from installed instruments, validated workflows, consumables pull-through, service relationships, regulatory familiarity, application know-how, and global sales coverage. | Medium-high |
| Management | Management has reshaped segments around customer markets, acquired BIOVECTRA, continued buybacks and dividends, and raised FY2026 guidance after Q2, but capital allocation depends on integration and margin discipline. | Medium |
| Financial trend | FY2025 revenue rose to $6.948 billion and Q2 2026 revenue rose 10.0% reported to $1.83 billion, with non-GAAP EPS guidance lifted to $6.00 to $6.10. | High |
| Valuation | At $131.14, A traded near 28.7x FY2025 GAAP EPS, 21.7x the $6.05 midpoint of FY2026 non-GAAP EPS guidance, and 32.2x FY2025 free cash flow per share. | Medium-high |
| Technical trend | Technical snapshots were mixed to constructive, with price above 20-day and 50-day moving averages, near short-term resistance around $133 to $135, and RSI near neutral. | Medium |
| Risk level | Main risks include cyclical lab instrument orders, China weakness, tariff and freight costs, pharma funding swings, BIOVECTRA integration, diagnostics reimbursement, and valuation compression. | Medium-high |
| AI confidence | High for descriptive facts and audited calculations, medium for forward scenarios and chart levels. | High data confidence |
| Investment certainty | Medium certainty. The page frames scenarios and monitoring rules, not a buy or sell instruction. | Medium |
A AI stock forecast
The A AI stock forecast uses scenario math around the $131.14 quote and Agilents raised FY2026 non-GAAP EPS guidance midpoint of $6.05. The audited three-year framework produced a bearish area near $109, a base area near $154, and a bullish area near $191 before dividends.
$185 to $195
More likely if core revenue growth stays near the high end of guidance, CrossLab services and consumables keep recurring demand resilient, China stabilizes, BIOVECTRA adds profitable growth, and the market keeps a premium multiple near 25x forward earnings.
$148 to $160
More likely if Agilent compounds EPS around mid single digits, maintains non-GAAP operating margin expansion, and investors value the company around a low 20s earnings multiple.
$105 to $112
More likely if lab instrument demand softens, China remains weak, tariff costs pressure margins, pharma budgets slow, or investors reprice the stock closer to 18x earnings.
A AI technical analysis
A AI technical analysis is constructive but not risk-free as of the July 8, 2026 data cutoff. The stock recovered after Q2 2026 results and traded above several 20-day and 50-day moving average snapshots, while short-term resistance sat near $133 to $135 and momentum remained closer to neutral than overbought.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $131.14 | Quote snapshots around the July 8, 2026 cutoff placed A near $131. |
| Near support | $130.33 to $126.27 | Financhill listed the 20-day EMA near $130.33 and the 50-day EMA near $126.27, making this the first pullback zone to monitor. |
| Deeper support | $125 area | AltIndex cited a 200-day moving average near $125, making a decisive break below that area a longer trend warning. |
| Near resistance | $133 to $135 | StockInvest and Financhill snapshots placed short-term moving-average resistance around $133.27 to $133.80, close to the post-earnings reaction zone. |
| Long-term resistance | $160.27 | MarketWatch reported a 52-week high of $160.27, which remains the upper reference point if the recovery extends. |
| Momentum | RSI roughly 56 | Financhill listed RSI near 56.47, a neutral reading rather than an exhausted momentum setup. |
| Volume | Average volume near 2.6 million shares | Google Finance listed average volume near 2.61 million shares, useful for judging breakout quality. |
| Volatility | About 18% below the 52-week high | Recent MarketWatch snapshots described A as still below its $160.27 52-week high despite the Q2 rebound. |
| Invalidation | Close below $125 | A decisive close below the 200-day area would weaken the post-Q2 recovery thesis. |
A AI trading strategy
The A AI trading strategy is a rules-based research framework for monitoring a lab tools stock after a guidance-driven recovery. It is not personal advice and should be paired with fresh chart data, filings, position sizing, and a defined invalidation level.
Watch for A to hold above the $126 to $130 moving average zone, then clear $133 to $135 on volume above average. A sustained move toward the $150 area would require follow-through in Q3 guidance and order commentary.
A close below $125 or a failed breakout after the next earnings update should invalidate the near-term recovery setup.
If A pulls back toward the $126 to $130 area without a negative guidance reset, compare price action with pharma, China, Applied Markets, and CrossLab commentary before assuming support is durable.
Do not average down without a maximum loss rule because life science tools stocks can gap on funding, China, tariff, or product-cycle news.
Track core revenue growth, non-GAAP operating margin, CrossLab recurring revenue, instrument orders, China demand, BIOVECTRA contribution, free cash flow, and buyback discipline.
Reduce confidence if EPS growth depends mainly on cost controls or tax effects instead of organic demand, margin quality, and cash conversion.
Investment research summary
Agilent helps laboratories identify, measure, validate, and maintain scientific workflows. Customers pay because accuracy, uptime, compliance, and validated methods are costly to rebuild from scratch.
The moat is practical rather than absolute. Installed instruments, service contracts, consumables, software, regulatory comfort, application expertise, and channel reach make switching slow, but rivals such as Thermo Fisher, Danaher, Waters, and Bruker keep pricing power in check.
The thesis fails if lab capex turns down, China demand stays weak, tariffs erode gross margin, recurring revenue cannot offset instrument softness, or BIOVECTRA fails to earn its strategic premium.
Management should be judged by segment focus, acquisition discipline, R&D productivity, buyback timing, working capital control, and whether FY2026 margin gains come from durable productivity instead of temporary cost cuts.
Agilent sits inside long-duration demand for biopharma research, diagnostics, food safety, environmental testing, advanced materials, and lab automation, but customer budgets still move with funding cycles and regional policy.
At roughly 21.7x the FY2026 non-GAAP EPS guidance midpoint, the stock requires continued recovery. Margin of safety improves if price revisits support while guidance and cash conversion stay intact.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| A price | $131.14 | Google Finance quote snapshot | July 8, 2026 |
| Market capitalization | $37.11 billion, verified as $131.14 x 283.0 million shares | financial_rigor.py market cap verification | July 8, 2026 |
| FY2025 revenue | $6.948 billion, cross-checked against rounded third-party $6.95 billion figures | Agilent FY2025 Form 10-K | July 8, 2026 |
| FY2025 net income | $1.303 billion | Agilent FY2025 Form 10-K | July 8, 2026 |
| FY2025 operating cash flow and capex | $1.559 billion operating cash flow and $407 million capex | Agilent FY2025 Form 10-K | July 8, 2026 |
| Cash and debt | $1.789 billion cash, $3.354 billion total short-term plus long-term debt | Agilent FY2025 Form 10-K | July 8, 2026 |
| Q2 FY2026 results | $1.83 billion revenue, $1.20 GAAP EPS, $1.49 non-GAAP EPS | Agilent Q2 FY2026 8-K summary | July 8, 2026 |
| FY2026 guidance | $7.39 billion to $7.49 billion revenue and $6.00 to $6.10 non-GAAP EPS | Agilent Q2 FY2026 8-K summary | July 8, 2026 |
| Segment revenue mix | FY2025 revenue: LSDM $2.726B, CrossLab $2.908B, Applied Markets $1.314B | Agilent FY2025 Form 10-K segment table | July 8, 2026 |
| Technical snapshot | 20-day EMA near $130.33, 50-day EMA near $126.27, RSI near 56.47 | Financhill technical analysis snapshot | July 8, 2026 |
This page is an informational research tool only and is not investment advice, financial advice, or a recommendation to buy or sell A stock. Forecast scenarios are based on available public data, technical snapshots, and stated assumptions as of the data cutoff date and may be wrong. Always verify current filings, prices, risks, and personal suitability before making financial decisions.
